文献速递脑血管病

中央视网膜动脉阻塞的静脉纤溶治疗:队列研究与更新个体水平荟萃分析

Intravenous Fibrinolysis for Central Retinal Artery Occlusion: A Cohort Study and Updated Patient-Level Meta-Analysis.
PubMed 文献 · Stroke · 2020-06-17

该前瞻性队列纳入112例急性中央视网膜动脉阻塞患者,其中25例接受静脉阿替普酶治疗。更新荟萃分析(238例)显示4.5小时内溶栓者恢复率37.3%,优于未治疗者的17.7%。

要点

  • 发病4.5小时内静脉阿替普酶与更高的视力恢复率相关。
  • 溶栓治疗越早,视力恢复率越高。
  • 结果支持开展随机安慰剂对照临床试验。

核心结论

  • 发病4.5小时内静脉阿替普酶与急性中央视网膜动脉阻塞患者更大概率获得良好视力结局相关。
  • 研究结果强烈支持推进随机安慰剂对照临床试验。

研究设计与样本

  • 前瞻性队列研究纳入2009年1月至2019年5月连续112例症状发作48小时内、视力<20/200的急性中央视网膜动脉阻塞患者。
  • 将队列结果纳入更新的系统综述与个体水平荟萃分析,荟萃分析共238例患者。

主要发现

  • 112例队列中25例(22.3%)接受静脉阿替普酶治疗,1例出现无症状性脑出血。
  • 4小时内就诊未治疗者视力恢复率11.6%,与溶栓者比较P=0.03。
  • 荟萃分析中4.5小时内溶栓者67例,视力恢复率37.3%;未治疗者恢复率17.7%。
  • 线性回归显示更早治疗与更高视力恢复率相关(P=0.01)。

关键数值与推荐

  • 静脉阿替普酶治疗时间窗为症状发作4.5小时内。
  • 荟萃分析中溶栓者恢复率37.3% vs 未治疗者17.7%。

临床怎么用

  • 对发病4.5小时内的急性中央视网膜动脉阻塞患者,可考虑静脉阿替普酶治疗以争取视力恢复。
  • 治疗决策需权衡无症状性脑出血等安全性事件。

局限性

  • 队列研究为非随机设计,溶栓组样本量较小(25例)。
  • 原文未报告荟萃分析的异质性或偏倚评估细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Central retinal artery occlusion results in sudden, painless, usually permanent loss of vision in the affected eye. There is no proven, effective treatment to salvage visual acuity and a clear, unmet need for an effective therapy. In this work, we evaluated the efficacy of intravenous tissue-type plasminogen activator (IV alteplase) in a prospective cohort study and an updated systematic review and meta-analysis. METHODS: We enrolled consecutive patients with acute central retinal artery occlusion within 48 hours of symptoms onset and with a visual acuity of <20/200 from January 2009 until May 2019. The primary outcomes were safety and functional visual acuity recovery. We compared rates of visual recovery between those treated with alteplase within 4.5 hours of symptom onset to those who did not receive alteplase (including an analysis restricted to untreated patients presenting within the window for treatment). We incorporated these results into an updated systematic review and patient-level meta-analysis. RESULTS: We enrolled 112 patients, of whom 25 (22.3% of the cohort) were treated with IV alteplase. One patient had an asymptomatic intracerebral hemorrhage after IV alteplase treatment. Forty-four percent of alteplase-treated patients had recovery of visual acuity when treated within 4.5 hours versus 13.1% of those not treated with alteplase (P=0.003) and 11.6% of those presenting within 4 hours who did not receive alteplase (P=0.03). Our updated patient-level meta-analysis of 238 patients included 67 patients treated with alteplase within 4.5 hours since time last known well with a recovery rate of 37.3%. This favorably compares with a 17.7% recovery rate in those without treatment. In linear regression, earlier treatment correlated with a higher rate of visual recovery (P=0.01). CONCLUSIONS: This study showed that the administration of intravenous alteplase within 4.5 hours of symptom onset is associated with a higher likelihood of a favorable visual outcome for acute central retinal artery occlusion. Our results strongly support proceeding to a randomized, placebo-controlled clinical trial.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mac Grory B, Nackenoff A, Poli S, et al. Intravenous Fibrinolysis for Central Retinal Artery Occlusion: A Cohort Study and Updated Patient-Level Meta-Analysis. Stroke. 2020. PMID: 32568646. doi:10.1161/STROKEAHA.119.028743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。